The phase Ib sabatolimab plus HMA trial reported an ORR of 71.4% (95% CI, 41.9–91.6) among 10 of 14 TP53-mutated HR-MDS patients (four of whom reached CR, 28.6%) [128]. The gene discussed is TP53; the disease is myelodysplastic syndrome.